Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.57 |
| ▸ | BTK | Q06187 | 5/20 | 0.51 |
| ▸ | JAK3 | P52333 | 3/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.49 |
| ▸ | AURKA | O14965 | 3/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.48 |
| ▸ | LCK | P06239 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.44 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1710229 | 1.00 | MAP4K4 (0.57) | MAP4K4BTKJAK3PDE10AAURKA | |
| SCHEMBL1710581 | 1.00 | MAP4K4 (0.57) | MAP4K4BTKJAK3PDE10AAURKA | |
| SCHEMBL13156590 | 0.94 | MAP4K4 (0.49) | MAP4K4BTKJAK3PDE10ASYK | |
| SCHEMBL1710218 | 0.94 | MAP4K4 (0.49) | MAP4K4BTKJAK3PDE10ASYK | |
| SCHEMBL1710216 | 0.94 | MAP4K4 (0.49) | MAP4K4BTKJAK3PDE10ASYK | |
| SCHEMBL4564058 | 0.93 | MAP4K4 (0.55) | MAP4K4BTKJAK3PDE10AAURKA | |
| SCHEMBL13833280 | 0.93 | MAP4K4 (0.55) | MAP4K4BTKJAK3PDE10AAURKA | |
| SCHEMBL16522585 | 0.93 | MAP4K4 (0.51) | MAP4K4BTKJAK3PDE10AAURKA | |
| SCHEMBL27775571 | 0.90 | MAP4K4 (0.47) | MAP4K4BTKJAK3PDE10AAURKA | |
| SCHEMBL13156552 | 0.88 | CKS1B (0.52) | MAP4K4PDE10APIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000507-B2 | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | INCYTE CORPORATION (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170190716-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | disclosed |
| US-9556197-B2 | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | INCYTE CORPORATION (US) | 2017-01-31 | — | — | US | disclosed |
| EP-2475659-B1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2015-10-28 | — | — | EP | disclosed |
| WO-2015027124-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2015-02-26 | — | — | WO | disclosed |
| US-20150057265-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2015-02-26 | — | — | US | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| WO-2011029802-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-20110059961-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-03-10 | — | — | US | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-20100130465-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-05-27 | — | — | US | disclosed |
| US-20100130465-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-05-27 | — | — | US | disclosed |
| WO-2010026122-A1 | HETEROCYCLIC PIM-KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010026122-A1 | HETEROCYCLIC PIM-KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| EP-2132177-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190716-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | MAP4K4 50/4885BTK 82/4885JAK3 86/4885 |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | AURKC, AURKA, AURKB | MAP4K4 322/4885BTK 2368/4885JAK3 1929/4885 |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | MAP4K4 85/4885BTK 16/4885JAK3 165/4885 |
| US-20100130465-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MAPK15, CDK15, MAP3K15 | MAP4K4 27/4885BTK 1777/4885JAK3 51/4885 |
| US-10000507-B2 | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | PIM1, PIM2, PIM3 | MAP4K4 50/4885BTK 82/4885JAK3 86/4885 |
| US-20110059961-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM3, PIM2 | MAP4K4 52/4885BTK 88/4885JAK3 63/4885 |
| US-20150057265-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | MAP4K4 50/4885BTK 82/4885JAK3 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.